Sydney, April 24, 2026, 06:18 AEST
- Cochlear has slashed its fiscal 2026 profit outlook to A$290 million–A$330 million, down sharply from its previous A$435 million–A$460 million range. The company pointed to weaker implant demand across developed markets and flagged ongoing uncertainty from the Middle East conflict.
- The stock tumbled a record 40.7% on Wednesday, then slid another 4.6% Thursday to finish at A$95.00.
- Jarden’s Steve Wheen and Tristan Maher called the downgrade “far worse than anticipated.” MarketWatch
Cochlear shares tumbled further on Thursday, dropping 4.6% to A$95.00 after the hearing-implant maker sharply cut its fiscal 2026 profit outlook. Blaming weaker demand across developed markets and ongoing uncertainty linked to Middle East conflict, Cochlear now expects annual profit to land between A$290 million and A$330 million—well below its previous range of A$435 million to A$460 million.
Size is key here. Morningstar puts Cochlear’s global cochlear implant share at roughly 60%. Still, the midpoint of the new guidance lands far short of the A$402.5 million Visible Alpha consensus, according to Reuters.
The warning hits as markets remain fragile. Reuters noted this downgrade joins a string of Australian profit warnings tied to war-driven shocks, rising costs, and flagging sentiment. Cochlear shares dropped another 4.6% by the end of Thursday, according to ABC, on top of their staggering 40.7% plunge on Wednesday.
Cochlear reported that implant revenue in developed markets held steady in the third quarter when measured at constant currency, taking foreign exchange swings out of the equation. Surgery volumes slipped, hit by limited hospital capacity, a slowdown in referrals from the hearing-aid channel, and weaker consumer sentiment—most notably among adult and senior patients.
The situation puts Cochlear in an uncomfortable spot. For years, the company has pointed to steady 10% annual growth among adults and seniors in developed markets, calling that group its main engine for future expansion. But Europe now faces fresh hurdles: lengthening surgery waitlists in the UK and Germany, plus strikes disrupting Italy and Spain.
Emerging markets showed some strength, though gains were uneven. Cochlear flagged the Middle East conflict as a potential driver of order cancellations and shipping setbacks. The company also warned that reduced reimbursement in China’s special access zones is set to drag premium-tier sales lower in the second half.
The hit to earnings stretches past just weak sales. Cochlear flagged a possible provision of up to A$10 million tied to Middle East receivables. Lower output? That’s expected to shave about a percentage point off gross margin, which is profit after production costs. Restructuring charges might run between A$18 million and A$25 million. Then there’s currency: a firmer Australian dollar could slice roughly A$25 million off second-half profit, after tax.
Chief Executive Dig Howitt called out that hearing loss among adults and seniors continues to be viewed as a “discretionary intervention”. Still, he expressed confidence in Cochlear’s market position and noted robust uptake for the Nucleus Nexa system. Cochlear
Broker response was swift and unsparing. Jarden’s Steve Wheen and Tristan Maher slammed the downgrade as “far worse than anticipated,” warning Cochlear’s track record on forecasts now threatens its valuation multiple. Morningstar analyst Shane Ponraj pointed to stubborn headwinds among adults and seniors. The Australian
Competitive landscape plays a role. Morningstar pegs Cochlear’s global market share at around 60%. Sonova, for its part, runs its cochlear-implant segment through the Advanced Bionics brand.
But it wasn’t a wipeout across the board. Services revenue climbed 13% in the third quarter, with Acoustics up 11%. Still, Jefferies flagged a bigger issue: are the problems Cochlear pointed to structural, or is this just a matter of postponed volumes?
Back in February, Cochlear warned investors it was likely to hit the bottom of its earlier guidance. Shares wrapped up Thursday at A$95.00, a drop after Reuters noted that Wednesday’s A$99.58 finish marked the lowest close since March 2016.
